Collectively, these data suggest that TP53 mutations do not predispose ALL cells to undergo forced mitotic entry in response to adavosertib or its combination with cytarabine despite on-target WEE1 kinase inhibition, but combination treatment favors induction of apoptotic cell death over cell cycle arrest. This evidence concerns the gene TP53 and acute lymphoblastic leukemia.